The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Neuroprotective and Anti–Human Immunodeficiency Virus Activity of Minocycline
Abstract
CONTEXT: The prevalence of human immunodeficiency virus (HIV) central nervous system (CNS) disease has not decreased despite highly active antiretroviral therapy. Current antiretroviral drugs are expensive, have significant adverse effects including neurotoxicity, and few cross the blood-brain barrier. OBJECTIVE: To examine the ability of minocycline, an antibiotic with potent anti-inflammatory and neuroprotective properties, to protect against encephalitis and neurodegeneration using a rapid, high viral load simian immunodeficiency virus (SIV) model of HIV-associated CNS disease that constitutes a rigorous in vivo test for potential therapeutics. DESIGN AND SUBJECTS: Five SIV-infected pigtailed macaques were treated with 4 mg/kg per day of minocycline beginning at early asymptomatic infection (21 days after inoculation). Another 6 macaques were inoculated with SIV but remained untreated. Blood and cerebrospinal fluid (CSF) samples were taken on days 7, 10, 14, 21, 28, 35, 43, 56, 70, 77, and 84, and all macaques were humanely killed at 84 days after inoculation, a time that corresponds to late-stage infection in HIV-infected individuals. MAIN OUTCOME MEASURES: Blood and CSF samples were tested for viral load by real-time reverse transcription-polymerase chain reaction and levels of monocyte chemoattractant protein 1 were quantitated by enzyme-linked immunosorbent assay. The presence and severity of encephalitis was determined by microscopic examination of tissues. Central nervous system inflammation was further assessed by measuring infiltration and activation of macrophages, activation of p38 mitogen-activated protein kinase and expression of amyloid precursor protein by quantitative immunohistochemistry. RESULTS: Minocycline-treated macaques had less severe encephalitis (P = .02), reduced CNS expression of neuroinflammatory markers (major histocompatibility complex class II, P = .03; macrophage marker CD68 , P = .07; T-cell intracytoplasmic antigen 1, P = .03; CSF monocyte chemoattractant protein 1, P = .001), reduced activation of p38 mitogen-activated protein kinase (P<.001), less axonal degeneration (beta-amyloid precursor protein, P = .03), and lower CNS virus replication (viral RNA, P = .04; viral antigen, P = .04). In in vitro analysis, minocycline suppression of HIV and SIV replication in cultured primary macrophages did not correlate with suppression of activation of p38-mitogen-activated protein kinase pathways, whereas suppression in primary lymphocytes correlated with suppression of p38 activation. CONCLUSIONS: In this experimental SIV model of HIV CNS disease, minocycline reduced the severity of encephalitis, suppressed viral load in the brain, and decreased the expression of CNS inflammatory markers. In vitro, minocycline inhibited SIV and HIV replication. These findings suggest that minocycline, a safe, inexpensive, and readily available antibiotic should be investigated as an anti-HIV therapeutic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
Cited by
O'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002148 · Cited by 1,278
TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation
Tang, Y., Wu, X., Lei, W., Pang, L., Wan, C., Shi, Z., Zhao, L., Nagy, T. R., Peng, X., Hu, J., et al. (2009) · Nature Medicine · doi:10.1038/nm.1979 · Cited by 1,165
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
HIV-associated neurocognitive disorder
Clifford, D. B., & Ances, B. M. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70269-x · Cited by 670
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70270-3 · Cited by 649
Neurological complications of HIV infection
McArthur, J. C., Brew, B. J., & Nath, A. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70165-4 · Cited by 554
HIV and antiretroviral therapy in the brain: neuronal injury and repair
Ellis, R., Langford, D., & Masliah, E. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2040 · Cited by 517
De Paiva, C. S., Corrales, R. M., Villarreal, A. L., Farley, W. J., Li, D.-Q., Stern, M. E., & Pflugfelder, S. C. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2006.02.004 · Cited by 451
Human immunodeficiency virus‐associated neurocognitive disorders: Mind the gap
McArthur, J. C., Steiner, J., Sacktor, N., & Nath, A. (2010) · Annals of Neurology · doi:10.1002/ana.22053 · Cited by 445
Griffin, M. O., Fricovsky, E., Ceballos, G., & Villarreal, F. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00047.2010 · Cited by 413
Recent advances in MMP inhibitor design
Fisher, J. F., & Mobashery, S. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7894-9 · Cited by 215
Williams, D. W., Eugenin, E. A., Calderon, T. M., & Berman, J. W. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0811394 · Cited by 212
Buckner, C. M., Luers, A. J., Calderon, T. M., Eugenin, E. A., & Berman, J. W. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9017-3 · Cited by 88
Minocycline treatment for HIV-associated cognitive impairment: Results from a randomized trial
Sacktor, N., Miyahara, S., Deng, L., Evans, S., Schifitto, G., Cohen, B. A., Paul, R., Robertson, K., Jarocki, B., Scarsi, K., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f0412 · Cited by 87
Self-citationYan, X., Jiang, E., & Weng, H.-R. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0222-3 · Cited by 77
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment
Nakasujja, N., Miyahara, S., Evans, S., Lee, A., Musisi, S., Katabira, E., Robertson, K., Ronald, A., Clifford, D. B., & Sacktor, N. (2013) · Neurology · doi:10.1212/wnl.0b013e31827b9121 · Cited by 67
Abrogated Inflammatory Response Promotes Neurogenesis in a Murine Model of Japanese Encephalitis
Das, S., Dutta, K., Kumawat, K. L., Ghoshal, A., Adhya, D., & Basu, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017225 · Cited by 65
Defaux, A., Zurich, M.-G., Honegger, P., & Monnet-Tschudi, F. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.04.053 · Cited by 40
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Metadata
- Authors
- Zink, M. C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-04-27
- Volume
- 293
- Issue
- 16
- Pages
- 2003
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1975447710
- Cited by
- 231
- References
- 2
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.